

ENRGISE pilot study will inform larger trial of IL-6 in seniors

July 27 2017



(HealthDay)—Data obtained from a pilot study, published online July 22

in the *Journal of the American Geriatrics Society*, will be used to plan a full-scale trial targeting interleukin (IL)-6 levels among older adults with low-to-moderate physical function.

Todd M. Manini, Ph.D., from the University of Florida in Gainesville, and colleagues conducted a multicenter randomized [pilot](#) trial of two interventions to reduce IL-6 levels at five university-based research centers. The target enrollment was 300 men and women aged 70 years and older with an average plasma IL-6 level between 2.5 and 30 pg/mL and low-to-moderate physical function. The authors randomized participants to losartan, omega-3 fish oil (ω -3), combined losartan and ω -3, or placebo. In order to reach a dose that was safe and effective for IL-6 reduction, a titration schedule was implemented.

The researchers anticipate that results from the ENabling Reduction of low-Grade Inflammation in SENiors (ENRGISE) Pilot Study will provide data on recruitment yields, feasibility, and medication tolerance and adherence. In addition, the trial will provide preliminary data to justify a larger sample size that can be used for a more definitive randomized trial.

"The ENRGISE Pilot Study will inform a larger subsequent trial that is expected to have important clinical and public health implications for the growing population of [older adults](#) with low-grade chronic inflammation and mobility limitations," the authors write.

More information: [Abstract](#)
[Full Text \(subscription or payment may be required\)](#)

Copyright © 2017 [HealthDay](#). All rights reserved.

Citation: ENRGISE pilot study will inform larger trial of IL-6 in seniors (2017, July 27) retrieved

19 April 2024 from <https://medicalxpress.com/news/2017-07-enrgise-larger-trial-il-seniors.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.